Moritake Iguchi, Hiromichi Wada, Felipe Martínez, Koji Hasegawa
{"title":"我们应该在心力衰竭患者中何时开始使用钠-葡萄糖共转运蛋白抑制剂？早期干预的重要性。","authors":"Moritake Iguchi, Hiromichi Wada, Felipe Martínez, Koji Hasegawa","doi":"10.15420/ecr.2022.62","DOIUrl":null,"url":null,"abstract":"www.ECRjournal.com Sodium–glucose co-transporter (SGLT2) inhibitors were primarily developed as anti-diabetic drugs to increase the excretion of glucose in the urine. However, SGLT2 inhibitors have been reported to have multifactorial effects, such as renal protection and improvement of myocardial energy metabolism and anaemia symptoms, which may exert protection against progression of heart failure beyond their mere diuretic action.","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2023-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/41/cb/ecr-18-e41.PMC10345959.pdf","citationCount":"0","resultStr":"{\"title\":\"When Should We Start Sodium-Glucose Co-transporter Inhibitors in Patients with Heart Failure? The Importance of Early Intervention.\",\"authors\":\"Moritake Iguchi, Hiromichi Wada, Felipe Martínez, Koji Hasegawa\",\"doi\":\"10.15420/ecr.2022.62\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"www.ECRjournal.com Sodium–glucose co-transporter (SGLT2) inhibitors were primarily developed as anti-diabetic drugs to increase the excretion of glucose in the urine. However, SGLT2 inhibitors have been reported to have multifactorial effects, such as renal protection and improvement of myocardial energy metabolism and anaemia symptoms, which may exert protection against progression of heart failure beyond their mere diuretic action.\",\"PeriodicalId\":45957,\"journal\":{\"name\":\"European Cardiology Review\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2023-06-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/41/cb/ecr-18-e41.PMC10345959.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Cardiology Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15420/ecr.2022.62\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Cardiology Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15420/ecr.2022.62","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
When Should We Start Sodium-Glucose Co-transporter Inhibitors in Patients with Heart Failure? The Importance of Early Intervention.
www.ECRjournal.com Sodium–glucose co-transporter (SGLT2) inhibitors were primarily developed as anti-diabetic drugs to increase the excretion of glucose in the urine. However, SGLT2 inhibitors have been reported to have multifactorial effects, such as renal protection and improvement of myocardial energy metabolism and anaemia symptoms, which may exert protection against progression of heart failure beyond their mere diuretic action.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
